Bethesda, MD
In spring 2016, the FDA released the long-awaited draft guidelines that brought generic drug manufacturers into the abuse-deterrent formulations market. This new regulatory framework comes at a time when public concerns about abuse of prescription opioids has never been higher — and yet obstacles to market uptake remain due to payer and prescriber hesitancy. This period of upheaval is why you cannot afford to miss the 4th Human Abuse Liability & Abuse-Deterrent Formulations conference — the largest and most specifically focused educational event devoted to improving trial designs, engineering less abuse-prone molecules and delivery systems, and tracking the performance and market uptake of opioids in order to document the success of abuse-deterrent methods. Over the past four years this event has brought more than 200 industry leaders together, and this year is going to have our most in-depth educational and networking opportunities yet!
